Issue Date: December 5, 2016
MedImmune, Abpro form research venture
MedImmune, the biologics division of AstraZeneca, and Abpro, a synthetic biology specialist, are collaborating in a spin-off company, AbMed, that will develop antibodies targeting angiopoietin-2 and vascular endothelial growth factor (Ang2-VEGF). AbMed will operate as a subsidiary of Abpro, which will receive development and commercialization rights to research programs. MedImmune will receive development, regulatory, and sales milestone and royalty payments. MedImmune will also take a minority equity stake in AbMed.
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society